用于 PET 成像应用的锰-52 螯合化学

IF 3.6 4区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Nuclear medicine and biology Pub Date : 2023-12-23 DOI:10.1016/j.nucmedbio.2023.108874
James M. Omweri , Volkan Tekin , Shefali Saini , Hailey A. Houson , Samith B. Jayawardana , Daniel A. Decato , Gayan B. Wijeratne , Suzanne E. Lapi
{"title":"用于 PET 成像应用的锰-52 螯合化学","authors":"James M. Omweri ,&nbsp;Volkan Tekin ,&nbsp;Shefali Saini ,&nbsp;Hailey A. Houson ,&nbsp;Samith B. Jayawardana ,&nbsp;Daniel A. Decato ,&nbsp;Gayan B. Wijeratne ,&nbsp;Suzanne E. Lapi","doi":"10.1016/j.nucmedbio.2023.108874","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Due to its decay and chemical properties, interest in manganese-52 has increased for development of long-lived PET radiopharmaceuticals. Its long half-life of 5.6 days, low average positron energy (242 keV), and sufficient positron decay branching ratio make it suitable for radiolabeling macromolecules for investigating slow biological processes. This work aims to establish suitable chelators for manganese-52 that can be radiolabeled at mild conditions through the evaluation of commercially available chelators.</p></div><div><h3>Methods</h3><p>Manganese-52 was produced through the nuclear reaction <sup>Nat</sup>Cr(p,n)<sup>52</sup>Mn by irradiation of natural chromium targets on a TR24 cyclotron followed by purification through ion exchange chromatography. The radiolabeling efficiencies of chelators: DOTA, DiAmsar, TETA, DO3A, NOTA, 4′-Formylbenzo-15-crown-5, Oxo-DO3A, and DFO, were assessed by investigating the impact of pH, buffer type, and temperature. <em>In vitro</em> stability of [<sup>52</sup>Mn]Mn(DO3A)<sup>−</sup>, [<sup>52</sup>Mn]Mn(Oxo-DO3A)<sup>−</sup>, and [<sup>52</sup>Mn]Mn(DOTA)<sup>2−</sup> were evaluated in mouse serum. The radiocomplexes were also evaluated <em>in vivo</em> in mice. Crystals of [Mn(Oxo-DO3A)]<sup>−</sup> were synthesized by reacting Oxo-DO3A with MnCl<sub>2</sub> and characterized by single crystal X-ray diffraction.</p></div><div><h3>Results</h3><p>Yields of 185 ± 19 MBq (5.0 ± 0.5 mCi) (n = 4) of manganese-52 were produced at the end of a 4 h, 15 μA, bombardment with 12.5 MeV protons. NOTA, DO3A, DOTA, and Oxo-DO3A chelators were readily radiolabeled with &gt;96 % radiochemical purity at all conditions. Manganese radiocomplexes of Oxo-DO3A, DOTA, and DO3A remained stable <em>in vitro</em> up to 5 days and exhibited different biodistribution profiles compared to [<sup>52</sup>Mn]MnCl<sub>2</sub>. The solid-state structure of Mn-Oxo-DO3A complex was determined by single-crystal X-ray diffraction.</p></div><div><h3>Conclusions</h3><p>DO3A and Oxo-DO3A are suitable chelators for manganese-52 which are readily radiolabeled at mild conditions with high molar activity, and demonstrate both <em>in vitro</em> and <em>in vivo</em> stability.</p></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"128 ","pages":"Article 108874"},"PeriodicalIF":3.6000,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0969805123006029/pdfft?md5=03b22d19bd51af10dd7051d5419ab246&pid=1-s2.0-S0969805123006029-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Chelation chemistry of manganese-52 for PET imaging applications\",\"authors\":\"James M. Omweri ,&nbsp;Volkan Tekin ,&nbsp;Shefali Saini ,&nbsp;Hailey A. Houson ,&nbsp;Samith B. Jayawardana ,&nbsp;Daniel A. Decato ,&nbsp;Gayan B. Wijeratne ,&nbsp;Suzanne E. Lapi\",\"doi\":\"10.1016/j.nucmedbio.2023.108874\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Due to its decay and chemical properties, interest in manganese-52 has increased for development of long-lived PET radiopharmaceuticals. Its long half-life of 5.6 days, low average positron energy (242 keV), and sufficient positron decay branching ratio make it suitable for radiolabeling macromolecules for investigating slow biological processes. This work aims to establish suitable chelators for manganese-52 that can be radiolabeled at mild conditions through the evaluation of commercially available chelators.</p></div><div><h3>Methods</h3><p>Manganese-52 was produced through the nuclear reaction <sup>Nat</sup>Cr(p,n)<sup>52</sup>Mn by irradiation of natural chromium targets on a TR24 cyclotron followed by purification through ion exchange chromatography. The radiolabeling efficiencies of chelators: DOTA, DiAmsar, TETA, DO3A, NOTA, 4′-Formylbenzo-15-crown-5, Oxo-DO3A, and DFO, were assessed by investigating the impact of pH, buffer type, and temperature. <em>In vitro</em> stability of [<sup>52</sup>Mn]Mn(DO3A)<sup>−</sup>, [<sup>52</sup>Mn]Mn(Oxo-DO3A)<sup>−</sup>, and [<sup>52</sup>Mn]Mn(DOTA)<sup>2−</sup> were evaluated in mouse serum. The radiocomplexes were also evaluated <em>in vivo</em> in mice. Crystals of [Mn(Oxo-DO3A)]<sup>−</sup> were synthesized by reacting Oxo-DO3A with MnCl<sub>2</sub> and characterized by single crystal X-ray diffraction.</p></div><div><h3>Results</h3><p>Yields of 185 ± 19 MBq (5.0 ± 0.5 mCi) (n = 4) of manganese-52 were produced at the end of a 4 h, 15 μA, bombardment with 12.5 MeV protons. NOTA, DO3A, DOTA, and Oxo-DO3A chelators were readily radiolabeled with &gt;96 % radiochemical purity at all conditions. Manganese radiocomplexes of Oxo-DO3A, DOTA, and DO3A remained stable <em>in vitro</em> up to 5 days and exhibited different biodistribution profiles compared to [<sup>52</sup>Mn]MnCl<sub>2</sub>. The solid-state structure of Mn-Oxo-DO3A complex was determined by single-crystal X-ray diffraction.</p></div><div><h3>Conclusions</h3><p>DO3A and Oxo-DO3A are suitable chelators for manganese-52 which are readily radiolabeled at mild conditions with high molar activity, and demonstrate both <em>in vitro</em> and <em>in vivo</em> stability.</p></div>\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"128 \",\"pages\":\"Article 108874\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2023-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0969805123006029/pdfft?md5=03b22d19bd51af10dd7051d5419ab246&pid=1-s2.0-S0969805123006029-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0969805123006029\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805123006029","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

导言由于锰-52的衰变和化学特性,人们对开发长寿命PET放射性药物的兴趣与日俱增。锰-52的半衰期长达5.6天,平均正电子能量低(242千伏),正电子衰变支化比足够大,因此适合用于对大分子进行放射性标记,以研究缓慢的生物过程。本研究旨在通过对市售螯合剂的评估,为可在温和条件下进行放射性标记的锰-52建立合适的螯合剂。方法在 TR24 回旋加速器上辐照天然铬靶,通过核反应生成 NatCr(p,n)52Mn,然后通过离子交换色谱法进行纯化。螯合剂的放射性标记效率:通过研究 pH 值、缓冲液类型和温度的影响,评估了 DOTA、DiAmsar、TETA、DO3A、NOTA、4′-甲酰基苯并-15-冠醚-5、Oxo-DO3A 和 DFO 等螯合剂的放射性标记效率。评估了[52Mn]Mn(DO3A)-、[52Mn]Mn(Oxo-DO3A)-和[52Mn]Mn(DOTA)2-在小鼠血清中的体外稳定性。还在小鼠体内对放射性络合物进行了评估。结果在用 12.5 MeV 质子轰击 4 小时、15 μA 后,产生了 185 ± 19 MBq(5.0 ± 0.5 mCi)(n = 4)的锰-52。在所有条件下,NOTA、DO3A、DOTA 和 Oxo-DO3A 螯合剂都很容易被放射性标记,放射性纯度为 96%。与[52Mn]MnCl2相比,Oxo-DO3A、DOTA和DO3A的锰放射性络合物在体外可保持稳定达5天,并表现出不同的生物分布特征。通过单晶 X 射线衍射确定了 Mn-Oxo-DO3A 复合物的固态结构。结论DO3A 和 Oxo-DO3A 是锰-52 的合适螯合剂,在温和的条件下很容易进行放射性标记,具有很高的摩尔活性,并且在体外和体内都表现出稳定性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chelation chemistry of manganese-52 for PET imaging applications

Introduction

Due to its decay and chemical properties, interest in manganese-52 has increased for development of long-lived PET radiopharmaceuticals. Its long half-life of 5.6 days, low average positron energy (242 keV), and sufficient positron decay branching ratio make it suitable for radiolabeling macromolecules for investigating slow biological processes. This work aims to establish suitable chelators for manganese-52 that can be radiolabeled at mild conditions through the evaluation of commercially available chelators.

Methods

Manganese-52 was produced through the nuclear reaction NatCr(p,n)52Mn by irradiation of natural chromium targets on a TR24 cyclotron followed by purification through ion exchange chromatography. The radiolabeling efficiencies of chelators: DOTA, DiAmsar, TETA, DO3A, NOTA, 4′-Formylbenzo-15-crown-5, Oxo-DO3A, and DFO, were assessed by investigating the impact of pH, buffer type, and temperature. In vitro stability of [52Mn]Mn(DO3A), [52Mn]Mn(Oxo-DO3A), and [52Mn]Mn(DOTA)2− were evaluated in mouse serum. The radiocomplexes were also evaluated in vivo in mice. Crystals of [Mn(Oxo-DO3A)] were synthesized by reacting Oxo-DO3A with MnCl2 and characterized by single crystal X-ray diffraction.

Results

Yields of 185 ± 19 MBq (5.0 ± 0.5 mCi) (n = 4) of manganese-52 were produced at the end of a 4 h, 15 μA, bombardment with 12.5 MeV protons. NOTA, DO3A, DOTA, and Oxo-DO3A chelators were readily radiolabeled with >96 % radiochemical purity at all conditions. Manganese radiocomplexes of Oxo-DO3A, DOTA, and DO3A remained stable in vitro up to 5 days and exhibited different biodistribution profiles compared to [52Mn]MnCl2. The solid-state structure of Mn-Oxo-DO3A complex was determined by single-crystal X-ray diffraction.

Conclusions

DO3A and Oxo-DO3A are suitable chelators for manganese-52 which are readily radiolabeled at mild conditions with high molar activity, and demonstrate both in vitro and in vivo stability.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nuclear medicine and biology
Nuclear medicine and biology 医学-核医学
CiteScore
6.00
自引率
9.70%
发文量
479
审稿时长
51 days
期刊介绍: Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
期刊最新文献
225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates Evaluation of chelating agents based on pyridine-azacrown compounds H4PATA, PATAM, and H4PATPA for 68Ga and 177Lu In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles The potential of targeted radionuclide therapy to treat hypoxic tumor cells New prospects for 89Zr-immuno-PET in brain applications – Alpha-synucleinopathies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1